Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluating the efficacy of radically open dialectical behavior therapy (RO-DBT) in patients with anorexia nervosa, study protocol for a randomized controlled clinical trial

  • Avila-Parcet, Aina|||0000-0002-7355-0420
  • Martin Blanco, Ana|||0000-0002-3917-0854
  • Gawron, Leonor Patricia|||0000-0003-0165-7349
  • Cano, Marta|||0000-0003-0675-9483
  • De la Peña-Arteaga, Víctor|||0000-0001-8627-2653
  • Carceller-Sindreu, Mar|||0000-0001-7504-3935
  • Soler, Joaquim|||0000-0001-8077-3641
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Faustino, Gloria
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Carmona i Farrés, Cristina|||0000-0002-7028-3697
Anorexia nervosa (AN) is a severe and disabling disorder, with relapse rates as high as 50% after the first episode, posing a significant challenge for clinicians. Most therapies excessively focus on nourishment, resulting in temporary weight restoration but with no improvements in general well-being and quality of life. Radically Open Dialectical Behavior Therapy (RO-DBT) is a transdiagnostic treatment designed to address overcontrol, a key aspect in the functioning of patients with AN. To date, no clinical trial (CT) has shown its efficacy in these patients or evaluated its neurobiological mechanism of action. A randomized CT in weight restored adult AN patients will be conducted, with one group receiving treatment as usual (TAU) and the other TAU plus RO-DBT, with the main outcome being quality of life. Secondary variables will include eating disorders (EDs) symptoms, overcontrol characteristics, autistic traits, and neuroimaging changes. The results will address a gap in knowledge regarding AN treatment, with the expectation that patients receiving TAU with RO-DBT will exhibit improved quality of life and experience fewer relapses at the one-year follow-up. This is the first study examining neuroimaging changes in RO-DBT to better understand its underlying mechanisms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neural Substrates of Psychotic Depression, Findings From the Global ECT-MRI Research Collaboration

  • Takamiya, Akihiro|||0000-0003-2985-6673
  • Dols, Annemiek
  • Emsell, Louise|||0000-0003-0011-4158
  • Abbott, Christopher|||0000-0001-6884-2464
  • Yrondi, Antoine|||0000-0002-2650-6080
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Jorgensen, Martin Balslev|||0000-0002-1321-8901
  • Nordanskog, Pia
  • Rhebergen, Didi
  • van Exel, Eric
  • Oudega, Mardien L.
  • Bouckaert, Filip
  • Vandenbulcke, Mathieu
  • Sienaert, Pascal|||0000-0002-0650-415X
  • Péran, Patrice
  • Cano, Marta|||0000-0003-0675-9483
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Jorgensen, Anders
  • Paulson, Olaf B.|||0000-0001-7712-8596
  • Hamilton, Paul
  • Kampe, Robin
  • Bruin, Willem Benjamin|||0000-0002-0672-8903
  • Bartsch, Hauke|||0000-0003-1486-4128
  • Ousdal, Olga Therese|||0000-0002-0728-3141
  • Kessler, Ute
  • van Wingen, Guido|||0000-0003-3076-5891
  • Oltedal, Leif|||0000-0003-3316-7950
  • Kishimoto, Taishiro
Psychotic major depression (PMD) is hypothesized to be a distinct clinical entity from nonpsychotic major depression (NPMD). However, neurobiological evidence supporting this notion is scarce. The aim of this study is to identify gray matter volume (GMV) differences between PMD and NPMD and their longitudinal change following electroconvulsive therapy (ECT). Structural magnetic resonance imaging (MRI) data from 8 independent sites in the Global ECT-MRI Research Collaboration (GEMRIC) database (n = 108; 56 PMD and 52 NPMD; mean age 71.7 in PMD and 70.2 in NPMD) were analyzed. All participants underwent MRI before and after ECT. First, cross-sectional whole-brain voxel-wise GMV comparisons between PMD and NPMD were conducted at both time points. Second, in a flexible factorial model, a main effect of time and a group-by-time interaction were examined to identify longitudinal effects of ECT on GMV and longitudinal differential effects of ECT between PMD and NPMD, respectively. Compared with NPMD, PMD showed lower GMV in the prefrontal, temporal and parietal cortex before ECT; PMD showed lower GMV in the medial prefrontal cortex (MPFC) after ECT. Although there was a significant main effect of time on GMV in several brain regions in both PMD and NPMD, there was no significant group-by-time interaction. Lower GMV in the MPFC was consistently identified in PMD, suggesting this may be a trait-like neural substrate of PMD. Longitudinal effect of ECT on GMV may not explain superior ECT response in PMD, and further investigation is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Glucocorticoid-based pharmacotherapies preventing PTSD

  • Florido Torres, Antonio Luis|||0000-0001-6184-0706
  • Velasco, Eric Raúl
  • Monari, Sílvia
  • Cano, Marta|||0000-0003-0675-9483
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Sandi, Carmen|||0000-0001-7713-8321
  • Andero Galí, Raül|||0000-0003-3641-8903
  • Perez-Caballero, Laura|||0000-0002-2315-2213
Posttraumatic stress disorder (PTSD) is a highly disabling psychiatric condition that may arise after exposure to acute and severe trauma. It is a highly prevalent mental disorder worldwide, and the current treatment options for these patients remain limited due to low effectiveness. The time window right after traumatic events provides clinicians with a unique opportunity for preventive interventions against potential deleterious alterations in brain function that lead to PTSD. Some studies pointed out that PTSD patients present an abnormal function of the hypothalamic-pituitary-adrenal axis that may contribute to a vulnerability toward PTSD. Moreover, glucocorticoids have arisen as a promising option for preventing the disorder's development when administered in the aftermath of trauma. The present work compiles the recent findings of glucocorticoid administration for the prevention of a PTSD phenotype, from human studies to animal models of PTSD. Overall, glucocorticoid-based therapies for preventing PTSD demonstrated moderate evidence in terms of efficacy in both clinical and preclinical studies. Although clinical studies point out that glucocorticoids may not be effective for all patients' subpopulations, those with adequate traits might greatly benefit from them. Preclinical studies provide precise insight into the mechanisms mediating this preventive effect, showing glucocorticoid-based prevention to reduce long-lasting behavioral and neurobiological abnormalities caused by traumatic stress. However, further research is needed to delineate the precise mechanisms and the extent to which these interventions can translate into lower PTSD rates and morbidity.